<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083807</url>
  </required_header>
  <id_info>
    <org_study_id>BXU529732</org_study_id>
    <nct_id>NCT04083807</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis</brief_title>
  <official_title>A Randomised Controlled Multicenter Single-blinded Phase III Study to Evaluate the Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis During Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of TISSEEL Lyo for haemostasis&#xD;
      in patients receiving peripheral vascular prosthetic expanded polytetrafluoroethylene (ePTFE)&#xD;
      conduits, as compared to a control arm treated with manual compression with surgical gauze&#xD;
      pads.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Actual">October 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants achieving hemostasis at 4 minutes after treatment</measure>
    <time_frame>Day 0 (4 minutes post-treatment to closure of surgical wound)</time_frame>
    <description>Performed on suture line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving hemostasis at 6 minutes after treatment</measure>
    <time_frame>Day 0 (6 minutes post-treatment to closure of surgical wound)</time_frame>
    <description>Performed on suture line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving hemostasis at 10 minutes after treatment</measure>
    <time_frame>Day 0 (10 minutes post-treatment to closure of surgical wound)</time_frame>
    <description>Performed on suture line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with intraoperative re-bleeding after hemostasis</measure>
    <time_frame>Day 0 (intraoperative)</time_frame>
    <description>Performed on suture line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with postoperative re-bleeding after hemostasis</measure>
    <time_frame>Day 1 (postoperative)</time_frame>
    <description>Performed on suture line. Requires surgical re-exploration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Adjunct to Hemostasis During Vascular Surgery</condition>
  <arm_group>
    <arm_group_label>TISSEEL Lyo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual compression with surgical gauze pads</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TISSEEL Lyo</intervention_name>
    <description>The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.</description>
    <arm_group_label>TISSEEL Lyo</arm_group_label>
    <other_name>Fibrin sealant Vapor Heated, Solvent/Detergent-Treated, with 500 IU/mL Thrombin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual compression with surgical gauze pads</intervention_name>
    <description>Surgical 4x4 inches gauze pads</description>
    <arm_group_label>Manual compression with surgical gauze pads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Male or female â‰¥ 18 ages;&#xD;
&#xD;
          -  Patients undergoing primary vascular surgery (i.e., conduit placement with an ePTFE&#xD;
             graft), including the following:&#xD;
&#xD;
               1. Arterio-arterial-bypass;&#xD;
&#xD;
                    -  Ilio-femoral bypass;&#xD;
&#xD;
                    -  Femoro-femoral bypass;&#xD;
&#xD;
                    -  Ilio-popliteal bypass;&#xD;
&#xD;
                    -  Femoro-popliteal bypass;&#xD;
&#xD;
                    -  Femoro-tibial vessel bypass&#xD;
&#xD;
               2. Arteriovenous shunting for dialysis access in the upper or lower extremity;&#xD;
&#xD;
        Intraoperative inclusion criterion:&#xD;
&#xD;
          -  Suture line bleeding eligible for study treatment is present after surgical&#xD;
             hemostasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent participation in another clinical study treatment with another&#xD;
             investigational drug or device within last 30 days;&#xD;
&#xD;
          -  Other vascular procedures during the same surgical session;&#xD;
&#xD;
          -  Arterio-arterial bypasses with more than two anastomoses;&#xD;
&#xD;
          -  Haemoglobin &lt;9.0 g/dL at screening;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Congenital or acquired coagulation disorders;&#xD;
&#xD;
          -  Prior kidney transplantation;&#xD;
&#xD;
          -  Heparin-induced thrombocytopenia;&#xD;
&#xD;
          -  Known prior exposure to aprotinin within the last 12 months;&#xD;
&#xD;
          -  Known hypersensitivity to aprotinin, heparin, blood products or other components of&#xD;
             the investigational product;&#xD;
&#xD;
          -  Unwilling to receive blood products.&#xD;
&#xD;
          -  Known severe congenital or acquired immunodeficiency;&#xD;
&#xD;
          -  Prior radiation therapy to the operating field;&#xD;
&#xD;
          -  Severe local inflammation at the operating field;&#xD;
&#xD;
          -  Positive results of any of the following the blood tests: HIV, syphilis, hepatitis B,&#xD;
             hepatitis C.&#xD;
&#xD;
          -  Emergency surgery.&#xD;
&#xD;
          -  Alcohol or drug abuse.&#xD;
&#xD;
        Intraoperative exclusion criteria:&#xD;
&#xD;
          -  Major intraoperative complications that required resuscitation or deviation from the&#xD;
             planned surgical procedure;&#xD;
&#xD;
          -  Intraoperative change in planned surgical procedure, which resulted in patient no&#xD;
             longer meeting preoperative inclusion criteria or having preoperative exclusion&#xD;
             criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>haemostasis</keyword>
  <keyword>tissue glue</keyword>
  <keyword>tissue sealing</keyword>
  <keyword>Ilio-femoral bypass</keyword>
  <keyword>Femoro-femoral bypass</keyword>
  <keyword>Ilio-popliteal bypass</keyword>
  <keyword>Femoro-popliteal bypass</keyword>
  <keyword>Femoro-tibial vessel bypass</keyword>
  <keyword>Arterio-arterial-bypass</keyword>
  <keyword>Arteriovenous shunting for dialysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

